Some aspects of this disclosure provide methods for treating obesity in subjects carrying a variant allele of the carboxypeptidase D (CPD) gene with perindopril, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, hydrate, or solvate thereof； a compound of Formula II, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, hydrate, or solvate thereof； or a compound of Formulae III-V, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, hydrate, or solvate thereof. Some aspects of this disclosure also provide methods for identifying a subject predisposed to obesity and/or sensitive to treatment with perindopril； a compound of Formula II, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, hydrate, or solvate thereof； or a compound of Formulae III- V, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, hydrate, or solvate thereof based on the subject carrying a variant allele of the CPD gene. Pharmaceutical compositions for treating obesity and kits for detecting a variant allele of the CPD gene and/or for identifying a subject who is predisposed to obesity or who would benefit from treatment with perindopril； a compound of Formula II, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, hydrate, or solvate thereof； or a compound of Formulae III- V, or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, hydrate, or solvate thereof are also provided.La présente invention concerne, dans certains aspects, des méthodes de traitement de l'obésité chez des sujets portant un allèle variant du gène de la carboxypeptidase D (CPD) avec le périndopril, ou son stéréoisomère, son tautomère, son polymorphe, son hydrate, son solvate ou son sel pharmaceutiquement acceptable ； un composé de formule II, ou son stéréoisomère, son tautomère, son polymorphe, son hydrate, son solvate ou son sel pharmaceutiquement acceptable ； ou un composé de form
